Impairment of the Ubiquitin-Proteasome Pathway by MethylN-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells

Selective killing of cancer cells by a small molecule targeting the stress response to ROS

(2011) Lakshmi Raj et al.   NATURE

Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole

(2010) Mohammad H Pourgholami et al.   BMC CANCER

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets

(2010) Lynn Bedford et al.   NATURE REVIEWS DRUG DISCOVERY

The ubiquitin proteasome system and its involvement in cell death pathways

(2009) F Bernassola et al.   CELL DEATH AND DIFFERENTIATION

BAX/BAK-Independent Mitoptosis during Cell Death Induced by Proteasome Inhibition?

(2009) E. Lomonosova et al.   MOLECULAR CANCER RESEARCH

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

(2009) M. J. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the ubiquitin system in cancer therapy

(2009) Daniela Hoeller et al.   NATURE

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Argyrin A Reveals a Critical Role for the Tumor Suppressor Protein p27kip1 in Mediating Antitumor Activities in Response to Proteasome Inhibition

(2008) Irina Nickeleit et al.   CANCER CELL

Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways

(2008) D. R. Fels et al.   CANCER RESEARCH

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH